James Dahlman is the McCamish Early Career Professor in the Department of Biomedical Engineering at Georgia Tech and Emory School of Medicine. His lab works at the interface of chemical engineering, genomics, and gene editing by applying big data approaches to nanomedicine. His trainees have developed DNA barcoded nanoparticles to measure how hundreds of nanoparticles deliver mRNA and siRNA in multiple cell types from a single animal in vivo, and the lab uses these approaches to deliver RNA outside the liver without targeting ligands. James was a co-founder and Board Chairman of Guide Therapeutics, which was acquired by Beam Therapeutics.
James has published in Nature, Nat Nano, Nat Biotech, Nat BME, Nat Metabolism, Nat Rev Cancer, Nat Rev Genetics, Science, Science Translational Medicine, Cell,Scientific American, and other high-impact journals. He has won awards including the BMES Rita Schaffer Award, ASGCT Outstanding New Investigator Award, Georgia Tech Outstanding Achievement in Early Career Research Award, Tech Review TR35, Controlled Release Society GDGE Award, and had his barcoding work described as a Top 10 Emerging Technology by the World Economic Forum.
All times are presented in the host university’s local time zone.
RNA-Based Drug and Diagnostic Development
(9:10am - 9:55am)